Key result
In trials of antihypertensive therapy, the rate ratio of major cardiovascular events to cardiovascular death decreased from 3.9 at low-moderate risk to 2.3 at very high risk.
Meta-Analysis
The ratio of total cardiovascular events to cardiovascular death decreases as baseline cardiovascular risk increases, allowing estimation of total cardiovascular risk from SCORE-calculated mortality risk.
No takes yet. Share an insight, caveat, or question.
Enables estimation of total major CV events from CV mortality via SCORE; extends risk stratification across baseline levels in antihypertensive trials.
Zambon et al. (2013) conducted a meta-analysis in Hypertension. Antihypertensive therapy was evaluated on Incidence of all-cause death, major cardiovascular events, and inclusive cardiovascular events relative to cardiovascular death. In trials of antihypertensive therapy, the rate ratio of major cardiovascular events to cardiovascular death decreased from 3.9 at low-moderate risk to 2.3 at very high risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: